{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:08:26Z","timestamp":1791454106218,"version":"4.3.3"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"\n PURPOSE<\/jats:title>\n \n Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, is approved for second-line treatment of locally advanced or metastatic urothelial carcinoma with susceptible\n FGFR3<\/jats:italic>\n alterations. Primary histology-agnostic analysis from the phase II RAGNAR study (ClinicalTrials.gov identifier:\n NCT04083976<\/jats:ext-link>\n ) indicated a clinical benefit with erdafitinib in Broad Panel Cohort (BPC) patients. We present tumor-specific updated efficacy and safety results from the BPC and tumor-agnostic findings from the Exploratory and Pediatric Cohorts of RAGNAR.\n <\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n \n The Broad Panel, Exploratory, and Pediatric Cohorts enrolled patients with target (selected)\n FGFR<\/jats:italic>\n alterations, nontarget\n FGFR<\/jats:italic>\n alterations, and any\n FGFR<\/jats:italic>\n alterations, respectively. Adults and pediatric patients (6 years and older) with advanced, unresectable, or metastatic disease who progressed after \u22651 prior line of systemic therapy and exhausted standard therapies were eligible. Erdafitinib 3-8 mg once daily (with possible uptitration) was administered orally until disease progression or intolerable toxicity.\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Objective response rates (ORRs) in the BPC were 10.0% (3 of 30) for high-grade glioma, 26.1% (6 of 23) for non\u2013small cell lung cancer, 28.6% for (2 of 7) low-grade glioma, 31.3% (5 of 16) for breast cancer, 33.3% (5 of 15) for head and neck squamous cell carcinoma, 55.6% (10 of 18) for pancreatic cancer, and 100% (5 of 5) for salivary gland cancer. The ORR was 3.8% (2 of 53) in the Exploratory Cohort. In the Pediatric Cohort (n = 11), there were one responder and seven patients with durable stable disease. Treatment-related adverse events (TRAEs) were consistent with the known safety profile of erdafitinib. Pediatric-specific TRAEs included epiphysiolysis and limb fracture.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSION<\/jats:title>\n \n Encouraging activity was observed for erdafitinib across tumor types in patients with advanced malignancies and selected\n FGFR<\/jats:italic>\n alterations who have exhausted treatment options. More limited activity was observed for erdafitnib in the Exploratory Cohort.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/po-25-01094","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:59:11Z","timestamp":1784145551000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Erdafitinib in Patients With Advanced Solid Tumors With\n FGFR<\/i>\n Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7137-2247","authenticated-orcid":true,"given":"Omar","family":"Carranza","sequence":"first","affiliation":[{"name":"Hospital Privado de Comunidad de Mar del Plata, Mar del Plata, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":true,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":true,"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-9157","authenticated-orcid":true,"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[{"name":"Hopp Children's Cancer Center (KiTZ), Heidelberg University Hospital, German Cancer Research Center and National Center for Tumor Diseases (NCT), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology, Gustave Roussy, INSERM U1360, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":true,"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, INSERM U981, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-2402","authenticated-orcid":true,"given":"Sameer","family":"Farouk Sait","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-599X","authenticated-orcid":true,"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-0066","authenticated-orcid":true,"given":"Graziela Z.","family":"Dal Molin","sequence":"additional","affiliation":[{"name":"Hospital Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Lugowska","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Precision Oncology in the Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Winter","sequence":"additional","affiliation":[{"name":"Bristol Haematology and Oncology Centre, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-7614","authenticated-orcid":true,"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[{"name":"Drug Development Department, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-8768","authenticated-orcid":true,"given":"Marcelo","family":"Corassa","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Antonio Prudente-A.C. Camargo Cancer Center, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibu","family":"Thomas","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Crow","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Xia","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-6052","authenticated-orcid":true,"given":"Hussein","family":"Sweiti","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-0157","authenticated-orcid":true,"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt419"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.8"},{"key":"e_1_3_10_5_2","article-title":"Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: A pooled analysis of early-phase clinical trials","author":"Grochot R","unstructured":"Grochot R, Joshi K, Cammarota A, et al: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: A pooled analysis of early-phase clinical trials. JCO Precis Oncol 10.1200\/PO-24-00896","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00275-9"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.610"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3119"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10058"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707358"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02772"},{"key":"e_1_3_10_12_2","volume-title":"CYRAMZA (ramucirumab) Injection [package insert]","year":"2022","unstructured":"CYRAMZA (ramucirumab) Injection [package insert]. Indianapolis, IN, Eli Lilly and Company, 2022"},{"key":"e_1_3_10_13_2","volume-title":"XELODA (capecitabine) Tablets [package insert]","year":"2015","unstructured":"XELODA (capecitabine) Tablets [package insert]. San Francisco, CA, Genentech, 2015"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.02.007"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25029"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70546"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30410"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411790"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.10007"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1499"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-01094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:59:16Z","timestamp":1784145556000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-01094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1200\/PO-25-01094"],"URL":"https:\/\/doi.org\/10.1200\/po-25-01094","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2501094"}}